AELIX Therapeutics, a Metrix Partners client, enrolled the first patient in its Phase I clinical trial of a therapeutic HIV vaccine in September 2017. The trial, AELIX-002, tests the company’s proprietary HTI vaccine in people living with HIV.

About the HTI vaccine
The HTI immunogen was designed by Dr Christian Brander, AELIX’s chief scientific officer and head of a research group at IrsiCaixa, and his colleagues. It combines regions of HIV that are targeted by T-cell responses in people who can control the virus without antiretroviral drugs. The goal is to train the immune system of other patients to respond in the same way.
A therapeutic vaccine differs from a preventive one. It is given to people who already have HIV, with the aim of helping their immune system control the virus, so that one day they might stop daily medication.
The AELIX-002 trial
AELIX-002 is a randomised, double-blind, placebo-controlled Phase I study in early diagnosed and treated patients. It evaluates the safety, tolerability and immunogenicity of a prime-boost regimen using different vaccine vectors, as described on ClinicalTrials.gov and Drug Development Technology. Results were later published in Nature Medicine.
Why the HIV vaccine trial mattered for AELIX
For a company built around one HIV vaccine concept, the first patient dosed marked the move from research to clinical development. It turned the HIV vaccine from a scientific design into a product candidate with human data, which is what investors and partners need before committing larger sums. It also changed the company’s cost base and reporting needs overnight.
What followed
In 2018, AELIX signed a clinical research collaboration with Gilead Sciences to test the HIV vaccine with Gilead’s vesatolimod. In November 2024, Gilead agreed to acquire AELIX’s HTI vaccine assets after promising Phase 1 and Phase 2 results.
Finance for a clinical-stage company
Entering the clinic changes a biotech company’s finances. Costs rise sharply and become harder to predict. Metrix supports clients through this stage with:
- Trial budgets tracked by site, vendor and milestone.
- Cash planning that reflects recruitment speed.
- Accounting for contracts with clinical research organisations.
- Reporting to investors and public funders.
- Preparation for the next financing round.
Five lessons for biotech companies entering the clinic
- Recruitment drives cost and timing. Slow enrolment delays data and increases spend.
- Budget for contingency. Protocol changes and extra sites are common.
- Accrue trial costs carefully. Costs should follow the work done, not invoices received.
- Use the data to raise. First clinical data is a key value point for investors and partners.
- Keep partners informed. Large companies watch early trials and may approach for collaborations.
What founders should prepare before a first trial
- A trial budget with milestones and payment schedules.
- Contracts with CROs and hospitals reviewed for cost and IP terms.
- A cash plan with scenarios for recruitment speed.
- Accounts reconciled to the statutory filings.
- An investor update plan around data readouts.
The search for a functional cure
Antiretroviral drugs control HIV but must be taken for life, because the virus hides in reservoirs that treatment cannot reach. A therapeutic HIV vaccine aims to strengthen the immune response so that the body controls the virus without daily drugs. The HTI approach is based on what the immune system does in the rare people who control HIV naturally. If an HIV vaccine of this type works, alone or in combination, it could change long-term care for millions of patients.
The path is long. Phase I studies establish safety and immune responses. Later studies test whether patients can stop treatment while keeping the virus under control. Each stage needs funding, partners and careful management of trial costs.
Metrix Partners in life sciences
Metrix has supported clinical-stage clients including Northern Biologics and Ona Therapeutics, and medtech companies such as DeepUll.






